The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics and pharmacodynamics following multiple rising intravenous doses of BI 3032950 in healthy male subjects and postmenopausal or surgically sterilised female subjects (women not of child bearing potential (WNOCBP)).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
40
BI 3032950
Placebo matching BI 3032950
SGS Life Science Services - Clinical Research
Edegem, Belgium
Occurrence of any treatment-emergent adverse event
Time frame: Up to Day 137
Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator
Time frame: Up to Day 137
Area under the concentration-time curve of the analyte in serum over a uniform dosing interval τ (AUCτ,)
Time frame: From Day 22 to Day 134
Maximum measured concentration of the analyte in serum (Cmax)
Time frame: From Day 22 to Day 134
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.